Chief Executive Officer and Chairman of the Board of Directors of Pharmacyclics. Mr. Duggan has been a member of the Board of Directors since September 2007 and was voted in as Chairman in September of 2008 after the resignation of its former Chairman. Since that time, Mr. Duggan has not assumed any pay or has received any options for his services to the company. In December 2008 and in March 2009, at a time the company needed operating funds, Mr. Duggan provided a loan to the company totaling $6.4M. With the receipts of funds raised through a rights offering, Mr. Duggan’s loan was paid back and he used the funds to participate at the same conditions as all other shareholders in the rights offering at his pro rata share. Alongside other biotech investors, Mr. Duggan invested since 2008 in three capital raises which were priced at market closes without any discounts. He purchased all his shares in Pharmacyclics outright and currently owns directly and indirectly approximately 20% of the outstanding shares.

Mr. Duggan has also served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. At that time Mr. Duggan became a Board Member of Intuitive Surgical, Inc. and served on its board until March 2011. Mr. Duggan has been an entrepreneur and industrialist for more than 30 years. He has participated as a CEO of, a director of, investor in and advisor to numerous small and large businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industry. Mr. Duggan has also assisted in corporate planning, capital formation and management for his various investments. In 1985 he received a Congressman’s Medal of Merit from Congressman Ron Paul and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. Mr. Duggan is a member of the University of California at Santa Barbara Foundation Board of Trustees.

Maky Zanganeh joined Pharmacyclics in August 2008. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert Duggan & Associates. While working with Mr. Duggan, she accepted a position as Director General (2007-2008) for the French government initiative biocluster project in France. Prior to joining Duggan & Associates, Dr. Zanganeh was worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle east and Africa (1998 - 2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France. She is fluent in French, German, Persian & English.

Dr. Lori Anne Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology Bone Marrow transplant unit at University of California, Los Angeles prior to joining the international biotechnology industry in 1995. Since then, she has held executive positions in a variety of companies that have provided her extensive experience in developing and commercializing oncologic/immunologic therapies. Her areas of responsibilities have included clinical, regulatory, medical affairs and licensing. She has worked for large biotechnology corporations (Genentech/Roche, Chiron/Novartis), and has served as Chief Medical Officer in start-up biotechs (ACT biotech, Syndax, Proteolix (acquired by Onyx) and Clinical Vice President at Genitope and Xencor. She has led US INDs, been directly involved in multiple EU and US strategic regulatory meetings, and secured Orphan Drug designations, Special Protocol Assessments, and Scientific Advice on numerous agents. Most recently she has been the principal of D2D, LLC, a consulting company that she founded. She has participated as a strategic clinical advisor and consultant to several corporations including Aton (acquired by Merck), DNAX (Schering Plough), Salmedix/Cephalon, Zymogenetics, Onyx, Raven, and Xoma, as well as a consultant for Boston and Bay area Venture Capital firms. Dr. Kunkel holds a Bachelor of Arts in Biology from University of California, San Diego; a medical degree from University of Southern California. She is board certified in Internal Medicine and Oncology.

David Loury joined Pharmacyclics as Vice President, Preclinical Sciences in May 2006 with 20 years of pharmaceutical industry experience. Most recently Dr. Loury served at Celera Genomics as Senior Director of Toxicology from April 2003 to April 2006. Prior to that, Dr Loury directed Drug Disposition, and Toxicology at Essential Therapeutics and IntraBiotics Pharmaceuticals from January 1996 to May 2001. Dr. Loury has held positions of increasing responsibility in Preclinical Safety at Syntex Corporation and Roche Pharmaceuticals. He is a Diplomate of the American Board of Toxicology. Dr. Loury received a B.S. degree in Environmental Toxicology and a Ph.D. in Pharmacology and Toxicology from the University of California, Davis.

Heow Tan joined Pharmacyclics in May 2012 after working for 26 years in the pharmaceutical industry. His experience in CMC included working with oral, semi-solid and parenteral products, and has successfully led the filing of several US NDAs, ANDA and European MAA. In Pharmacyclics, he is responsible for CMC Development, Global Manufacturing and Supply Chain. Prior to Pharmacyclics, Heow worked as Senior Vice President, Technical Operations for both Collegium Pharmaceutical and PreCision Dermatology (a spun off company of Collegium). In both companies, he was responsible for CMC Product Development, Manufacturing and Supply Chain activities. Prior to Collegium and PreCision, he worked at Praecis Pharmaceuticals Inc., Waltham, Massachusetts as Vice President of Industrial Operations and Development; He had also served as the Director of Manufacturing Operations for SciClone Pharmaceuticals Incorporated, San Mateo, California. Heow started his career in the pharmaceutical industry working for Syntex Laboratories in Palo Alto, California, serving as the Manager of Manufacturing Engineering and Manager of Materials Control. He obtained his M.S. in Engineering from the Ohio State University and his MBA from the Santa Clara University, California. .

Maria Fardis joined Pharmacyclics in April 2011 and served multiple roles including Vice President, alliance and global project management. Prior to joining the company, Dr. Fardis held increasingly senior positions in the project and portfolio management department at Gilead. She managed projects in antiviral, oncology, and cardiovascular therapeutic areas while at Gilead. Prior to joining the project and portfolio management, Dr. Fardis worked as a senior scientist in medicinal chemistry in Gilead, Intrabiotics, and Kosan Biosciences. She received her Ph.D. in Organic Chemistry from U. C. Berkeley. Dr. Fardis received her Bachelor of Science degree from University of Illinois, Urbana- Champaign.

Josh Brumm joined Pharmacyclics in August of 2012. Previously, Mr. Brumm served as Chief Financial Officer and Senior Vice President for ZELTIQ Aesthetics, Inc. having global responsibility for Finance, IT and Administration. Mr. Brumm also served ZELTIQ as Vice President, Corporate Development and Investor Relations, helping take the company public in October of 2011, as well as Senior Managing Director of International Sales launching the company’s first commercial product in all markets outside of the United States and Canada. Prior to joining ZELTIQ, Mr. Brumm served as Director of Finance at Proteolix, Inc. (acquired by Onyx Pharmaceuticals), a private biotechnology company focused on the development of therapeutics targeting certain cancers, including Multiple Myeloma, and immunological conditions. Prior to joining Proteolix, Mr. Brumm held the position of Investment Banking Associate as a member of the West Coast Healthcare Team at Citigroup Global Markets, Inc. As an entrepreneur, Mr. Brumm founded Nu-Ag Distributing, LLC, an agricultural sales and consulting company specializing in cotton and grain production. He also served Nu-Ag Distributing as the company’s Chief Executive Officer until its sale in June of 2007. Mr. Brumm started his career at Morgan Stanley as an Investment Banking Analyst for the West Coast Healthcare Team. Mr. Brumm holds a B.A. in Business Administration, summa cum laude, from the University of Notre Dame.

Paula S Boultbee joined Pharmacyclics in April 2012. She has more than 20 years of experience in Oncology commercialization including extensive global and USA launch experience gained from the brands Glivec/Gleevec (imatinib), Camptosar (irinotecan) and Aromasin (exemestane). Her expertise has been acquired through increased responsibilities in both small and large pharmaceutical companies. While at Amgen she led the life cycle management efforts of the erythropoietic proteins and EGFR inhibitor Vectibix, and the pre-marketing efforts of a number of preclinical molecules, companion diagnostics, and devices. At Pharmacia (Pfizer) , she held positions with growing responsibility in Sales, Brand management, and Country and Regional leadership roles. During her tenure at Novartis she led the global launch for the corporate flagship product Glivec/Gleevec: a product that is today helping thousands of patients to live a fuller life. Most recently she has worked as an independent consultant supporting pharmaceutical companies building their commercial platforms leading them to successful product launches, fundraising initiatives, targeted acquisitions and licensing agreements. She has a Nursing degree from Sweden and speaks fluent Swedish, Finnish, Italian and English. .

Mr. Erdtmann began his career in Europe as an investment banker. He was accepted into the Investment Banking Program of Commerzbank in Germany after he graduated with distinction from the Westfaelische Wilhelms Universitaet in Muenster, majoring in Financing and Banking. He was later recruited by the asset management arm of Commerzbank and became a portfolio manager for international clients. The portfolio assets under management exceeded $1Billion Dollars. In 1994 he co- founded a German-based real estate company, United Properties Immobilien & Anlagen GmbH, which to date has successfully developed over 30 different projects and manages a portfolio of over 250 units. His main area of responsibility has been setting up the organization and overseeing the financial aspects of its operations. Mr. Erdtmann came to the US in the mid- nineties to manage the assets for a US equity pool and several European investors. He became actively involved in some of the holding companies and served on several of their boards. Building on his European network, he has since consulted high net-worth individuals and closed-end funds, and actively advised in the selection of US investments for over $500 Million. Furthermore he finalized over $120 Million of equity and debt transactions for private equity partnerships.

Christophe Suchet joined Pharmacyclics in March 2013 as VP Information Technology. Mr. Suchet has more than 20 years of experience in various IT leadership positions and in consulting. Prior to joining Pharmacyclics, Mr. Suchet has held various IT Senior leadership positions at Genentech (9 years) leading large and global applications groups (ERP, Enterprise, Development...). Mr. Suchet led organizations to define and implement IT strategies closely aligned with business drivers, demonstrated large project management expertise, and successfully managed global and cross-functional teams. Prior to Genentech, Mr. Suchet held for 2 years a position at 3Com as IT senior manager in charge of Enterprise, ERP and Sales applications. Mr. Suchet also has 10 years of management consulting background working for KPMG Consulting and PricewaterhouseCoopers, involved primarily with ERP implementations for various industries. Christophe holds a Master of Sciences from AgroParisTech (Top engineering school in France) as well as a Bachelor degree in Accounting (part of CPA curriculum in France).

Gregory Hemmi has served as Vice President, Chemical Operations since May 2006. Dr. Hemmi served as Senior Director, Chemical Development from January 2001 to April 2006 and as Director, Chemical Development from December 1997 to December 2000. Other positions held at Pharmacyclics include Group Leader, Chemical Development from May 1995 to November 1997 and Scientist from June 1992 to April 1995. After graduating with a B.S. in Chemistry, Dr. Hemmi received a Ph.D. from the University of Texas at Austin under the direction of Professor Jonathan L. Sessler.

Dr. Jesse Seton McGreivy is a hematologist/oncologist by training with over seven years of industry experience developing oncology therapeutics. He received his bachelor degree from University of California, Berkeley and medical degree from The Ohio State University. He completed an internal medicine internship and residency at the Georgetown University Hospital and, subsequently, a hematology/oncology fellowship at the Lombardi Cancer Center at Georgetown University Hospital. At the Lombardi Cancer Center, Dr. McGreivy served as the Chief Fellow and was involved as a sub-investigator in the phase I clinic. He also worked as a Clinical Scientist at Hoffman-La Roche and as a Clinical Research Medical Director at Amgen, developing novel oncology therapeutics in phase Ib through III clinical trials. Dr. McGreivy has been the clinical lead in biomarker development programs as well as in clinical pharmacology studies. He is a board certified oncologist and has expertise in both solid tumors as well as malignant hematology.

Joseph J. Buggy has served as Vice President, Research since September 2007. From May 2006 to August 2007, Dr. Buggy served as Senior Director, Cancer Biology. From November 2001 to April 2006, he served as Director, Department of Biology at Celera Genomics, a biotechnology company. From June 1996 to October 2001, he was a staff scientist at AXYS Pharmaceuticals, Inc., a biotechnology company. Prior to that Dr. Buggy worked as a scientist at Bayer Corporation in West Haven, CT. Dr. Buggy received a Ph.D. in Molecular, Cellular, and Developmental Biology from Indiana University and a B.S. degree in Microbiology from the University of Pittsburgh.

Manmeet Soni joined Pharmacyclics in Sep 2012 as Corporate Controller and Executive Director of Finance and is responsible for all Accounting, Treasury, Tax and SEC reporting functions in the Company . He has over 15 years of experience in accounting, auditing, advisory, taxation and internal audit services. Previously, Manmeet worked in ZELTIQ Aesthetics. Inc. where he served as a controller, Senior Director of Finance responsible for accounting, SEC and treasury functions.  Prior to ZELTIQ, Manmeet spent over 10 years with PricewaterhouseCoopers (PwC) in various positions in accounting and advisory services.  Most recently he worked as Senior Manager in the Life Science and Venture Capital Group of the PwC San Jose office providing audit and advisory services to various public and privately held companies in the pharmaceutical, biotechnology, software and semiconductor space.  He graduated from Hansraj College at Delhi University in India. He is also a Certified Public Accountant, licensed in the state of California and Chartered Accountant from India. 

Rick Love joined Pharmacyclics as Vice President, Legal in June 2012. Rick has over 19 years of experience working as in-house counsel in the biotech/pharma industry. For the past three years, he worked for the IPSEN Group, most recently in the position of Vice-President, Head of Patents, U.S.A. Before IPSEN, he practiced in the areas of intellectual property and corporate law for five years at Tercica, Inc., beginning as Senior Director, Intellectual Property & Licensing and ending as Vice-President, Intellectual Property & Licensing. Before Tercica, he served as Senior Director, Intellectual Property for three years at InterMune, Inc. Before InterMune, he worked for eight years at Genentech, Inc. as Patent Counsel. He holds a J.D. from Golden Gate University School of Law and a B.A. in Mathematics from Hamilton College.

Scott Shearer joined Pharmacyclics as Vice President, Global Quality in June 2012 with 17 years of pharmaceutical industry experience. Most recently Dr. Shearer served as Senior Director of Quality at Teikoku Pharma USA from May 2009 to May 2012 where he oversaw all components of Quality. Prior to that, he served as Senior Director of Quality and Analytical Chemistry at Cerimon Pharmaceuticals from December 2007 to April 2009. Dr. Shearer held positions of increasing responsibility with various Johnson & Johnson pharmaceutical companies from 1999 to 2007. He began his career at Fort Dodge Animal Health (now Pfizer). Dr. Shearer received a B.A. degree in Chemistry from Kenyon College and a Ph.D. in Analytical Chemistry from the University of Vermont.

Urte (pronounced “Ulta”) Gayko, PhD is SVP of Global Regulatory Affairs. She joined PCYC in 2012 with 15 years of regulatory and clinical experience in oncology/hematology drug and in vitro diagnostics (IVD) development spanning all development phases. Previously Urte worked at Nodality Inc- a start-up biotech company recognized as the most promising company in the personalized medicine space- where she served as VP of Regulatory and Clinical Affairs for various biomarker and IVD products. Prior to that she worked at Amgen Inc . in regulatory and clinical development on several oncology therapeutics and supportive care products covering phase 1-4 regulatory development stages. Urte is originally from Germany and came to the US to perform her PhD research in cellular biology at Harvard University, MA. She is passionate to participate in the translation of novel scientific understanding of disease biology into therapeutic products and improvements for patients, doctors and care takers.